Pancreatic Cancer Incidence Has Risen, Yet Survival Outcomes Have Improved

Commentary
Video

Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.

As part of Pancreatic Cancer Awareness Month, Mehmet Sitki Copur, MD, FACP, spoke with CancerNetwork® about current data related to pancreatic cancer incidence and survival outcomes.

According to Copur, a medical director of Oncology and adjunct professor of Medical Oncology/Hematology at the University of Nebraska Medical Center, a medical oncologist/hematologist at Morrison Cancer Center of Mary Lanning Healthcare, and gastrointestinal editorial advisory board member for the journal ONCOLOGY, pancreatic cancer is approximately the eighth to tenth most common cancer diagnosis in 2024. However, the incidence of this disease is projected to rise; by 2030, pancreatic cancer is anticipated to become the second-leading cause of cancer-related death across the US. Regardless, Copur noted that the 5-year survival rate among patients with pancreatic cancer has improved since the 1970s.

Transcript:

[Pancreatic cancer] used to be a rare cancer and a deadly cancer with no treatments. Right now, it is the eighth to tenth most common cancer and 3% of all new cancers as of 2024, and new diagnoses are expected to be [approximately] 66,000 [in 2024]. What is so important about this disease, even though it’s [currently] the eighth or tenth most common [disease], it is almost on its way to becoming the [second-leading cause of cancer-related death]. The [first-leading cancer] for many years has been lung [cancer], with 160,000 deaths a year. Pancreatic cancer used to be in the third, fourth, or fifth range. Now, as of 2020, it reached up to the colorectal cancer death rate, and they are expecting, by 2030, that pancreatic cancer will be the [second-leading cause of cancer-related death]. The reason for this is that it has been notoriously resistant to available treatments.

During my fellowship, pancreatic cancer was like a death sentence. Over the decades, the 5-year survival was only 2% back in the 1970s. Now, it came up to 7% as of 2024. The most recent Pancreatic Cancer Action Network presentation gave us an optimistic number of 12% of 5-year survival, which is unheard of in this disease.

Epidemiology

Epidemiology

Projected Cancer-Related Deaths

Projected Cancer-Related Deaths

Trends in 5-year cancer survival

Trends in 5-year cancer survival

5-year pancreatic cancer survival

5-year pancreatic cancer survival

All images are posted with the permission of Mehmet Sitki Copur, MD, FACP.

Reference

Pancreatic cancer facts. Hirshberg Foundation for Pancreatic Cancer Research. Accessed November 21, 2024. https://tinyurl.com/mrpf34j2

Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.
Related Content